ReviewBlood research2026
Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms.
Review in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma cell neoplasms (PCNs) are a group of malignant neoplasms originating from the monoclonal expansion of immunoglobulin-secreting, terminally differentiated B cells, i.e., plasma cells (PCs). PCNs include monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma (solitary plasmacytoma of the bone and extramedullary plasmacytoma), multiple myeloma (MM)/plasma cell myeloma, and rare PCNs associated with paraneoplastic syndromes. MM is a multifocal, bone marrow-based clonal PCN associated with end-organ damage and a monoclonal paraprotein (M protein) in the serum and/or urine. Morphologically, MMs are typically composed of mature to atypical PCs with a typical immunophenotype (CD38 + bright, CD138 + , CD19-, and monotypic light-chain expression), which are usually diagnostically straightforward. However, rare cases with morphological variants or immunophenotypic aberrancies may pose diagnostic challenges. Small, mature-appearing PC variants of MM at times may be difficult to differentiate from mature B-cell lymphomas with plasmacytic differentiation, such as lymphoplasmacytic lymphoma and marginal zone lymphoma, particularly in core needle biopsies. CD20 + and cyclin D1 + MM may mimic mantle cell lymphoma. Plasmablastic and pleomorphic/anaplastic variants are prone to present as extramedullary lesions mimicking plasmablastic lymphoma (PBL) or various types of lymphomas with pleomorphic/anaplastic morphology. Moreover, neoplastic PCs may exhibit aberrant expression of CD3, CD4, CD117, and cyclin D1, leading to potential diagnostic pitfalls. Diffuse CD30 expression with anaplastic morphology may be mistaken for anaplastic large-cell lymphoma. In rare instances, the neoplastic cells of PCNs are positive for Epstein-Barr virus (EBV), more frequently in cases with plasmablastic morphology and extramedullary involvement, which may raise suspicion for PBL. In this review, we emphasize the rare morphological and immunophenotypic features and variants of PCNs and utilize a few examples to highlight the diagnostic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.